Inventing new medicines to address illnesses and diseases that lack good treatment options only solves part of the problem.
Drug discovery is a high-risk, high-cost endeavor, with over 90% of candidates failing in clinical development. A significant proportion of these failures stem from unresolved biopharmaceutic ...
Artificial intelligence is revolutionizing drug discovery and antibody engineering, accelerating the creation of new ...
Stocktwits on MSN
Gelteq preclinical study demonstrates enhanced oral delivery of oil-soluble and poorly soluble drugs using its gel-based platform
Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based developer of advanced gel-based oral delivery ...
Insilico Medicine has developed a new class of small molecule inhibitors targeting diacylglycerol kinase alpha (DGKα) designed to restore T cell ...
The Global Oral Drug Delivery Market is poised for growth driven by technological advances in drug delivery systems, ...
Software solutions today are equally important, as they enable integration of disparate automated unit operations with data ...
The newly granted U.S. patent, No. 12,492,178, includes claims to the drug substance of EMP-01, and is expected to provide exclusivity through 2043. This patent identifies a highly-crystalline, ...
Nanotube pathways enhance drug delivery in bladder cancer, improving hydroxycamptothecin penetration and efficacy in animal ...
A new review in Chinese Medical Journal details progress in nanocarrier-based cancer therapy. It analyzes polymeric, lipidic, ...
The rise of AMR in pathogenic bacteria poses serious challenges to the control and management of infectious diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback